XenoPort's Horizant tripped up by GSK manufacturing delay
This article was originally published in Scrip
Executive Summary
GlaxoSmithKline's manufacturing delays are yet another stumbling block for XenoPort's Horizant (gabapentin enacarbil) for the treatment of restless leg syndrome (RLS) and postherpetic neuralgia following a dispute over GSK's efforts to sell the drug.